

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Hirofumi KODA *et al.* (as corrected)) Confirmation No.: 8307
Application No.: 10/594,905) Group Art Unit: Unassigned
Filed: September 29, 2006) Examiner: Unassigned
For: PERIPHERAL BLOOD FLOW-IMPROVING)
COMPOSITION)

Commissioner for Patents
U.S. Patent and Trademark Office

Customer Window Mail Stop: New Application Amendment AF Issue Fee
Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT (IDS)

Under 37 C.F.R. § 1.97(b): Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. To the undersigned's knowledge, this IDS is being filed before the mailing date of a first Office Action on the merits, before the mailing date of a first Office Action on the merits after filing an RCE under § 1.114, or within three months of the application filing date.

Under 37 C.F.R. § 1.97(c): Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. This IDS is being filed after the events recited in § 1.97(b) but, to the undersigned's knowledge, before the mailing date of a Final Office Action, a Notice of Allowance, or another action that closes prosecution in the application.

The fee of \$180.00 set forth in § 1.17(p) is included herein; or
 Applicant submits that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

Under 37 C.F.R. § 1.97(d): Pursuant to 37 C.F.R. §§ 1.56 and 1.97(d), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. This IDS is being filed after the events recited in § 1.97(c) but before payment of the issue fee.

The fee of \$180.00 set forth in § 1.17(p) is included herein; and
 Applicant submits that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

Under 37 C.F.R. § 1.97(i): Pursuant to 37 C.F.R. §§ 1.56 and 1.97(i), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. This IDS is being filed after the events recited in § 1.97(d). Applicant requests that the IDS be placed in the file.

A search report or other listing of documents from a counterpart, related, or other application dated July 12, 2005 and having documents cited thereon was previously submitted for the Examiner's consideration on September 29, 2006. Any of these documents not previously cited, and any additional documents are listed on the PTO Form 1449.

Applicant respectfully requests that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. As for any document listed on the accompanying PTO-1449 that is in a language other than English, relevance can be understood from an enclosed English abstract or at least partial translation or from mention in the specification or in a search report for a corresponding application.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that any of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicant reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should any of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this Application, including fees due under 37 C.F.R. § 1.16 and 1.17 which may be required and including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0573. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,

DRINKER, BIDDLE & REATH LLP

Dated: August 1, 2007


Jeffrey G. Killian
Registration No. 50,891

CUSTOMER NO. 055694

DRINKER, BIDDLE & REATH LLP
1500 K Street, N.W., Suite 1100
Washington, D.C. 20005-1209
Tel: 202.842.8800; Fax: 202.842.8465

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Attorney Docket No.: 47487-0005	Serial No.: 10/594,905
	Applicants Hirofumi KODA <i>et al.</i> (as corrected)	Page 1 of 1
PTO Form 1449	Filing Date: September 29, 2006	Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation	
							YES	NO
		00/51548	Sep. 8, 2000	WO				
		9900721	Oct. 17, 2000	BR				X
		9901909	Oct. 31, 2000	BR				X
		2000-334044	Dec. 5, 2000	JP			X	
		2001-039854	Feb. 13, 2001	JP			Abstract	
		2002-20246	Jan. 23, 2002	JP			X	
		2002-515401	May 28, 2002	JP			X	
		2003-523945	Aug. 12, 2003	JP			Abstract	
		2004-171	Jan. 8, 2004	JP			X	

OTHER DOCUMENTS

(Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

Search Report dated July 12, 2005 for International Application No. PCT/JP2005/006325 filed March 31, 2005

YEUNHWA GU *et al.*, "The Blood Estradiol-17 β , Testosterone and Progesterone of Male and Female Mice Change", Suzuka University of Medical Science, Mie-Suzuka, Jan. 10, 2004, pp. 14-19, Vol. 148, No. 1, Japan

Examiner _____ Date Considered _____

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.